© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Cilostazol entered the pharmaceutical scene during a time when treating peripheral vascular diseases called for better tools than just lifestyle changes or surgical options. In the late 1980s, Japanese researchers focused on platelet aggregation and blood flow, aiming to craft a molecule that could improve walking distances for patients with intermittent claudication. After years of synthesis and animal testing, cilostazol moved into human trials, ultimately earning approval in both Japan and the United States during the late 1990s and early 2000s. Early clinicians faced skepticism from peers accustomed to older drugs, but walking improvement in patients gradually quieted doubts. The backstory of cilostazol reflects grit, dogged experimental work, and a strong faith in targeting platelet pathways.
Doctors use cilostazol to help individuals walk farther and feel less pain in their legs during exercise, especially for those grappling with the narrowing of arteries. The compound sits in the family of phosphodiesterase type 3 (PDE3) inhibitors, and the tablet form remains the most widely prescribed. Most patients pop a 100 mg tablet twice a day, although some require a lower 50 mg dose due to drug interactions or side effects. Manufacturers package cilostazol in blister packs or bottles, always labeled with clear dosing and contraindications for anyone with heart failure, based on real-world safety evidence.
Cilostazol often appears as a white or off-white crystalline powder, offering little taste and minimal odor. The molecule carries a molecular weight of about 369.46 g/mol, with the formula C20H27N5O2. Its moderate solubility in organic solvents, and low water solubility, make it tricky when compounding oral dosage forms. The melting point falls in the range of 160–163°C, so pharmacists know it stores well at room temperature on drug shelves.
Tablets need to meet strict content uniformity, dissolution rates, and tablet hardness as regulated by pharmacopeias in the US, EU, and Japan. Product inserts warn about food interactions, emphasizing administration at least 30 minutes before or two hours after a meal for best absorption. To comply with true safety, every label stresses avoiding use in patients with congestive heart failure, a warning added after clinical trials showed increased mortality in this group. Prescription bottles highlight expiration dates and lot numbers for recall purposes, reflecting the experience of quality control failures from past pharmaceutical recalls.
Synthesizing cilostazol requires a multistep pathway. Chemists start with benzyl nitriles and manipulate side chains until they reach the unique tetrazole ring fused to the quinolinone core. Specialized equipment keeps reaction conditions clean—some intermediates must avoid water and oxygen. Purification relies on chromatography, and final steps include vacuum drying to achieve that signature powder. This process only reached its current efficiency after dozens of failed batches earlier in development, highlighting the trial-and-error reality behind every active pharmaceutical ingredient on the market.
Medicinal chemists in both industry and academia have fiddled with cilostazol's core structure, hoping to create derivatives with more potent antiplatelet effects or greater blood vessel dilation. Substituting various groups at the quinolinone or tetrazole rings sometimes boosts selectivity for PDE3, but often at the cost of increased toxicity. Oxidation, sulfonation, or methylation reactions occasionally yield new analogues. Most of these variants never left the research bench due to lackluster clinical gains or unmanageable side effects, but these failed analogues taught scientists about the goldilocks zone for cardiovascular drugs.
Cilostazol goes by many names depending on market—Pletaal in Japan, Pletal in the United States—and carries aliases in chemical registries like OPC-13013 or 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone. This mix of trade and chemical names sometimes confuses new pharmacists, but most patients stick with the trade name listed in their country’s formulary.
Pharmacists and technicians wear gloves and avoid inhaling dust when handling bulk cilostazol powder for compounding. Tablets rarely generate dust after production, so secondary exposure risk remains low for patients and staff. Clinical experience, gathered from over twenty years of prescribing, shows typical side effects such as headache, palpitations, and gastrointestinal discomfort. Most patients tolerate the drug, but monitoring for bleeding risks continues through routine follow-up, especially in anyone already on antiplatelet or anticoagulant therapy. Nurses and doctors keep an eye out for rare but serious events, including ventricular arrhythmias, given the drug’s potent effects on platelet behavior and blood circulation.
Doctors most often prescribe cilostazol for intermittent claudication due to peripheral arterial disease. Some researchers have explored its use in stroke prevention, though other antiplatelet agents compete strongly in this space. In diabetic patients with poor lower limb circulation, cilostazol sometimes offers a last-resort improvement in walking capacity. Off-label use in vascular dementia has popped up in smaller studies, but no large-scale approval exists. A handful of veterinary cases even document cilostazol for rare circulatory problems in dogs.
Cilostazol’s journey didn’t end at approval. Early studies focused almost exclusively on walking distance, but modern trials now probe more subtle changes—improved quality of life, leg pain reduction, and long-term vascular health outcomes. Pharmacogenomics research tries to connect genetic markers with better or worse responses, pushing medicine closer to customized dosing. Scientists also trial various combination regimens, such as cilostazol with statins or other antiplatelets, hoping for synergistic cardiovascular protection without an explosion in side effects. The focus now has shifted from just clinical endpoints toward underlying mechanisms—how cilostazol affects endothelial function, smooth muscle migration, or inflammation—all with an eye toward smarter therapies tomorrow.
Toxicologists learned early that cilostazol’s safety margin narrows in patients with advanced heart failure. These risks played out in the large CAST trial, forcing black-box label warnings. Animal models flagged dose-dependent increases in arrhythmia risk, especially with high chronic dosing. Researchers have also probed reproductive toxicology, finding no teratogenic effects in standard mammal models at human doses, but advising caution during pregnancy just the same. Post-marketing surveillance in the real world has flagged cases of bleeding events, typically in elderly patients with polypharmacy. Decades of experience reinforce these findings, shaping cautious protocols for new patients, particularly among vulnerable groups such as the elderly and those with cardiac histories.
Looking ahead, clinicians and scientists see several frontiers for cilostazol. There’s growing interest in harnessing its endothelial effects to prevent microvascular complications in diabetes, or to extend stent patency after surgical interventions. New delivery methods, such as modified-release formulations, seek to smooth out blood levels and limit side effects. Some biotech firms experiment with nano-formulations aimed at better tissue targeting. Worldwide, more countries have begun evaluating cilostazol for inclusion in their formularies, and continued basic research may yet unearth new disease targets for this established molecule. The cornerstone lies in balancing risk and benefit with patient-specific insights, drawing on new data as it arrives, and keeping a patient’s walking and well-being at the center of every prescribing decision.
Leg cramps and pain make getting around tough for a surprising number of people. Peripheral arterial disease, or PAD, blocks blood flow to the legs. Simple things—taking the dog out or walking at the grocery store—can turn into painful chores. Over time, even climbing stairs or walking to the front door can become nearly impossible.
Doctors try to help people walk further and with less pain. Cilostazol entered the scene as one way to give folks a better shot at staying mobile. The drug keeps blood moving through narrowed leg arteries. It acts almost like a chemical traffic cop, stopping platelets from clumping and making the blood vessels open up wider.
Cilostazol steps in with a one-two punch. It thins the blood and widens arteries at the same time. That dual action means more blood and oxygen to leg muscles. The result? Many people walk longer distances before pain locks up their legs. Research backs this up. In one study highlighted by the American Heart Association, people taking cilostazol managed up to 50% greater walking distance than those who just relied on lifestyle changes.
The medicine isn’t just for pain. It lowers the chance of more serious problems cropping up, like non-healing wounds or, worse, amputations caused by severe PAD. Cilostazol doesn’t cure blocked arteries, but it buys time and lets people reclaim their routines.
Doctors usually reach for cilostazol after exercise therapy or walking regimens fall short. The medicine isn’t for everyone. People with heart failure shouldn’t take it. Side effects like headache or diarrhea sometimes show up, forcing a switch in therapy. But for those who tolerate it, the benefits can mean the difference between watching life from a window and joining in.
Family members often wonder what else they can do to help a loved one facing PAD. Smoking is enemy number one—a single cigarette steals hard-earned gains. Managing cholesterol, blood sugar, and blood pressure matters, too. Yet cilostazol holds a real place, especially for people without better options.
New medicines get the spotlight, but sometimes older drugs like cilostazol work just as well. Doctors know about it, but many patients do not. In my clinic, folks often feel frustrated by limited choices. They light up once they discover a pill that might help.
Cost can be a roadblock, though cilostazol is now generic. That means people with Medicare or standard prescription coverage usually pay less. Still, insurance hang-ups or an unfamiliar name on the pharmacy shelf can leave some patients missing out.
Cilostazol doesn’t erase arteries hardened by years of smoking or diabetes. It gives people a way to enjoy more of life outside four walls. More conversations happen on park benches and around neighborhood blocks. Every additional hundred steps mean something.
By watching out for drug interactions, sticking with exercise, and catching early changes in walking ability, patients and families can keep PAD from tightening its grip. Sometimes a small pill opens the door to bigger possibilities.
Cilostazol comes up in doctor visits for people dealing with poor circulation, especially in the legs. I remember a family member who started using it after struggling to walk to the mailbox. Doctors recommend Cilostazol because it helps widen blood vessels and keeps platelets from clumping. This combination makes it easier for blood to move through narrowed arteries, easing leg pain while walking, a problem called intermittent claudication. The impact on daily movement can feel like a small miracle, but as with most prescription drugs, there’s a flip side: side effects.
Upset stomach shows up a lot in people starting Cilostazol. Nausea or diarrhea become common conversations in support groups and doctor’s offices. This isn’t just a little discomfort. It can make simple meals stressful or leave someone stuck near the bathroom all day. Headaches often follow, sometimes powerful enough to disrupt sleep or ruin plans. For some, their hearts start racing. Cilostazol can cause a faster heartbeat, sometimes with a pounding in the chest. For people with heart issues like heart failure, this isn’t just uncomfortable—it can be dangerous.
Dizziness stops many from moving as much as they want. I’ve seen people steady themselves on furniture after standing up too quickly. This matters for older adults, especially those living alone, as it boosts the risk of falls. Back pain and muscle aches add to the list. These aches stack up, turning basic tasks like tying shoes into frustrating battles.
Beyond the common stuff, other rare but serious reactions exist. White blood cell counts can drop, leaving people more open to infections. Doctors also look for signs of bleeding and easy bruising, since blood-thinning raises those risks. Any sign of blood in stools or severe nosebleeds means it’s time to call a healthcare provider, fast.
Doctors trust Cilostazol for treating specific artery problems, but they listen carefully to patient concerns. For upset stomach, taking the pill with meals sometimes brings relief. Hydration helps with headaches and can keep dizziness at bay. If side effects make life miserable, a doctor can adjust the dose or switch to another drug. In a few stubborn cases, stopping Cilostazol altogether remains the only answer.
It helps to keep a daily diary of symptoms. That record becomes gold during follow-up visits, giving real data beyond vague memories. Pharmacists also play a big part—they’re ready to answer side effect questions or flag dangerous interactions with other drugs.
Information on side effects isn’t just a list to skim over. It’s a heads-up that drugs can bring problems alongside benefits. Regular check-ins with a healthcare provider matter more than ever. Nobody expects to face scary side effects alone. Real-world support and medical know-how work best as a team. When someone’s mobility and heart health both hang in the balance, being honest about side effects doesn’t just help the patient—it sharpens everyone’s focus on what care really looks like.
Sources:Cilostazol helps people live better with peripheral artery disease. Instead of just getting by with pain in the legs while walking, many folks find that this medicine lets them walk farther before that ache kicks in. Doctors rely on it as part of a plan to improve daily quality of life for adults who feel hobbled by poor circulation. This isn’t some quick fix; the benefits build up with regular use. Taking it the right way matters a lot.
Cilostazol usually comes as a tablet you take by mouth. Most doctors will tell you to take it twice a day, morning and evening. Here’s the trick: you get the full benefit on an empty stomach. That means waiting at least a half hour before or two hours after you eat. Putting food in the stomach with cilostazol can blunt how much of the medicine gets into your system. I’ve heard from plenty of folks who started off taking it with breakfast, only to find later that they weren’t getting the results they’d hoped for.
Missing doses sounds harmless, but it adds up. People who have the best results set a daily rhythm—a glass of water by the bed, an alarm on the phone, something to help stick to the schedule.
Blood thinners and other heart medicines often make up a big part of the prescription list for anyone needing cilostazol. There’s a real risk for bruises, bleeding, or pounding heart rate if medicines stack up the wrong way. Letting a doctor or pharmacist know about every pill or supplement in the cabinet keeps surprises to a minimum. Grapefruit juice has a knack for throwing off how the body processes cilostazol, too. Many people don’t think about their morning juice, but it can really throw a wrench into things.
Some folks get headaches or feel their heartbeat pick up when starting cilostazol. Usually, these settle down. If they don’t, or if anything unusual pops up—like black or tarry stools, new bruises, or anything that feels scary—it’s time to check in with a healthcare provider.
Skipping doses or taking this drug with food might sound minor at first. In reality, things work better and safer with a routine. In one study from the American Journal of Medicine, people who took this medication as directed saw longer walking distances, and their side effects didn’t jump out of range. Being consistent—without extra doses or skipping out—keeps those odds strong. Most insurance plans cover cilostazol, but not always the brand name. Generic versions give the same relief, so folks on a budget can ask their pharmacist about money-saving options.
Nobody likes feeling chained to a pillbox, but for a medicine like cilostazol, putting in the effort pays off. Besides sticking to the empty-stomach rule, bringing up any new symptoms fast makes a difference. Letting trusted friends or family know about the medicine helps keep an extra set of eyes out for those warning signs. The real goal isn’t just to fill a prescription. It’s to give legs a fighting chance to walk farther, with less pain, in daily life.
Health isn’t one-size-fits-all, but respecting the way this medicine works gives folks a real shot at reclaiming a bit more independence. That’s worth every bit of the extra attention it takes each day.
Cilostazol lands on the prescription list for adults dealing with intermittent claudication, a leg pain that walks hand in hand with poor blood flow. The goal here revolves around better walking distance and less pain. What surprises some folks in the clinic is how easily this medicine can trip over other common prescriptions, leading to messy side effects. Paying close attention before mixing things up helps people dodge risks like bleeding or heart troubles. No one wants a medication that helps one problem but stirs up another.
Cilostazol thins blood by slowing down platelet clumping. If a person already takes a blood thinner, such as warfarin, clopidogrel, or even aspirin, things can get dicey. Studies highlight that combining Cilostazol with other blood thinners may leave people more likely to bruise, bleed from the gums, or see blood in their urine. Numbers back this up—data from post-market surveillance reports pinpoint increases in serious bleeding for those mixing antiplatelets or anticoagulants with Cilostazol.
Statins, like simvastatin and atorvastatin, join the daily pillbox for lots of older adults. Both drugs pass through the liver, relying on similar CYP enzymes. Grapefruit juice or certain antibiotics block those enzymes, letting Cilostazol and statins pile up in the blood. The result: higher chances for headaches, faster heartbeats, or aching muscles. Personal experience as a pharmacist showed the frequency with which long lists of heart meds and cholesterol pills created confusion. Only careful review of everything someone takes prevented mix-ups.
Seizure medicines such as carbamazepine or phenytoin kick the liver into high gear, causing Cilostazol to clear out faster. Antifungals and some antibiotics slow liver actions, meaning a person might end up with double the amount of Cilostazol. Both extremes—too little or too much—risk side effects. Patients calling in with pounding headaches or lightheadedness usually took something new alongside Cilostazol. By checking for things like ketoconazole, erythromycin, or rifampin, providers spot the problem before it grows.
Full transparency with health professionals about every pill, supplement, and even a glass of juice counts for a lot. Periodic blood tests and talking about any new or odd symptom speeds up detecting trouble. Automated pharmacy systems flag serious risks, but trusting software alone never beats a face-to-face conversation. Pharmacists who see the big picture piece together patterns missed during a rushed doctor visit.
The science tells us which pills spell trouble together. What keeps people safe is a team approach, where patients understand what’s on the line and ask the right questions. Knowing how easily one drug can throw another off course helps everyone walk a little straighter, with fewer surprises along the way.
Cilostazol comes up as a blood-thinner meant to help with leg pain linked to clogged arteries, but it isn’t for everyone. People facing heart failure, both mild and severe, shouldn’t even think about taking this drug. I’ve seen friends try to manage cardiovascular issues and doctors keep the lines clear: the risk of death goes up with cilostazol for heart failure patients, according to solid trials and regulatory warnings. Modern medicine gears dietary advice, exercise, and different meds for them instead.
Anyone who’s dealt with bleeding disorders or suffered major bleeds gets put at risk with cilostazol. This drug messes with platelets so wounds or gut ulcers can become real threats. I know a woman whose father took blood thinners and had a stomach bleed so bad he ended up down for a week. You can’t gamble here. Scarred stomach lining or recent strokes from bleeds rule out cilostazol completely.
Cilostazol can stretch out the heartbeat’s Q-T interval and roll the dice on dangerous arrhythmias. Doctors keep people with certain rhythm issues—like long QT syndrome—away from cilostazol. These problems don’t always show up until an EKG, but skipping that checkup just to save time isn’t smart; the risk is too real, especially for families with a history of sudden cardiac events.
This drug gets processed in the liver and leaves the body through the kidneys. If either organ stops pulling its weight, cilostazol or its byproducts pile up and trouble follows. Real-life cases of drug toxicity aren’t rare when someone with kidney or liver failure tries to go on cilostazol just for a shot at better walking. Safer approaches rely on drugs with shorter half-lives and better known safety records in these patients.
Some patients react badly to cilostazol itself. Swelling, rash, or wheezing don’t stay small problems. The fact is, those with allergies must stay alert for ingredients, since reactions can trigger hospital visits. Besides that, cilostazol interacts with a load of common meds: certain antifungals, erythromycin, and even grapefruit juice can boost its effects or side effects. For people juggling plenty of pills—especially older adults—checking every interaction gets serious.
Some medications reach the baby before or after birth, and not enough real-world studies cover cilostazol’s safety for pregnant women or nursing infants. Doctors play it safe and recommend steering clear—most would rather switch patients to drugs with longer safety records during these stages. I’ve seen family members grilled on every med at prenatal visits for good reason. There’s a gap in research here worth fixing.
So what do we do for people shut out from cilostazol who still struggle with leg artery disease? Tailored walking programs, supervised rehab, and focusing harder on diet make all the difference. For many, simple aspirin and stopping smoking bring more improvement than a new prescription ever could. More research on safer options would help those edged out by cilostazol’s risks.
| Names | |
| Other names |
Pletal OB-BO1 OPC-13013 |
| Pronunciation | /saɪˈlɒs.tə.zɒl/ |
| Identifiers | |
| CAS Number | 73963-72-1 |
| Beilstein Reference | 124229 |
| ChEBI | CHEBI:3698 |
| ChEMBL | CHEMBL745 |
| ChemSpider | 5057 |
| DrugBank | DB00290 |
| ECHA InfoCard | 100.119.626 |
| EC Number | EC 3.1.4.17 |
| Gmelin Reference | 103664 |
| KEGG | D07719 |
| MeSH | D020831 |
| PubChem CID | 5328526 |
| RTECS number | RG5444000 |
| UNII | 2Y1W8Q5515 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C20H27N5O2 |
| Molar mass | 369.463 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.1 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 2.8 |
| Vapor pressure | 1.34E-10 mmHg |
| Acidity (pKa) | 13.86 |
| Basicity (pKb) | 9.98 |
| Magnetic susceptibility (χ) | -78.3e-6 cm³/mol |
| Dipole moment | 3.47 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -34 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -7925 kJ/mol |
| Pharmacology | |
| ATC code | B01AC23 |
| Hazards | |
| Main hazards | Bleeding, headache, palpitations, diarrhea, dizziness |
| GHS labelling | GHS labelling of Cilostazol: "Warning; Hazard statements: H302, H315, H319, H335; Precautionary statements: P261, P264, P271, P280, P301+P312, P305+P351+P338 |
| Pictograms | ❌🤰🚗🥛💊🍊 |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. |
| Flash point | Flash point: **273.3°C** |
| Autoignition temperature | 572°C |
| Lethal dose or concentration | LD50 (oral, rat): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse: 2,280 mg/kg (oral) |
| NIOSH | MF8380000 |
| PEL (Permissible) | 3 mg/m³ |
| REL (Recommended) | 100 mg twice daily |
| IDLH (Immediate danger) | IDLH not established |
| Related compounds | |
| Related compounds |
Pletaal Vorpaxar Dipyridamole Pentoxifylline Ticlopidine Clopidogrel Prasugrel |
